P3 - SERUM PROTEOMIC BIOMARKERS FOR LUNG CANCER DETECTION AND PROGNOSIS

P3 - 用于肺癌检测和预后的血清蛋白质组生物标志物

• 批准号: 8092832
• 负责人: William L Bigbee
• 金额: $ 23.97万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8092832
• 关键词: Algorithms; Angiogenic Factor; Antibodies; Arts; Autoantibodies; Benign; Biochemical; Biological; Biological Assay; Biological Markers; Blood specimen; Breast; Cancer Detection; Cancer Model; Cancer Patient; Case Series; Characteristics; Chest; Classification; Cleaved cell; Clinical; Collaborations; Colon; Detection; Development; Diagnosis; Diagnostic; Discrimination; Disease; Disease Progression; Early Diagnosis; Enzymes; Etiology; Evaluation; Excision; Extracellular Matrix; Fractionation; Goals; Growth; Growth Factor; Immune response; Lead; Lung; Lung diseases; Lung nodule; MALDI-TOF Mass Spectrometry; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Mass Spectrum Analysis; Methods; Modality; Modeling; Molecular; Newly Diagnosed; Operative Surgical Procedures; Outcome; Patients; Pattern; Peptide Hydrolases; Peptides; Performance; Population; Protein Isoforms; Proteins; Proteome; Proteomics; Public Health; Radiofrequency Interstitial Ablation; Recurrence; Reporting; Reproduction spores; Research; Resolution; Resources; Sampling; Screening procedure; Series; Serological; Serum; Serum Proteins; Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Staging; Symptoms; System; Technology; Testing; Therapeutic; Time; Tumor-Derived; University of Pittsburgh Cancer Institute; analytical method; base; cancer initiation; cancer recurrence; case control; chemokine; clinical Diagnosis; cohort; cytokine; follow-up; high risk; improved; lung cancer screening; novel; outcome forecast; pre-clinical; predictive modeling; prognostic; programs; receptor; tumor